David G Mummy1, Katherine J Carey2, Michael D Evans3, Loren C Denlinger4, Mark L Schiebler5, Ronald L Sorkness6, Nizar N Jarjour4, Sean B Fain7. 1. Department of Radiology, Duke University, Durham, NC; Center for In Vivo Microscopy, Duke University, Durham, NC. 2. Department of Medical Physics, University of Wisconsin-Madison, Madison, Wis; Department of Radiology, University of Wisconsin-Madison, Madison, Wis. 3. Clinical and Translational Science Institute, University of Minnesota-Twin Cities, Minneapolis, Minn. 4. Division of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin-Madison, Madison, Wis. 5. Department of Radiology, University of Wisconsin-Madison, Madison, Wis. 6. School of Pharmacy, University of Wisconsin-Madison, Madison, Wis. 7. Department of Medical Physics, University of Wisconsin-Madison, Madison, Wis; Department of Radiology, University of Wisconsin-Madison, Madison, Wis; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, Wis. Electronic address: sfain@wisc.edu.
Abstract
BACKGROUND: There is an unmet need for an objective biomarker to predict asthma exacerbations. OBJECTIVE: Our aim was to assess the ventilation defect percent (VDP) on hyperpolarized helium-3 magnetic resonance imaging as a predictor of exacerbation frequency following imaging. METHODS: Subjects underwent hyperpolarized helium-3 and conventional clinical measurements, including pulmonary function tests, during a period of disease stability, and exacerbations were recorded prospectively over the following 2 years. We used a Poisson regression tree model to estimate an optimal VDP threshold for classifying subjects into high- versus low-exacerbation groups and then used statistical regression to compare this VDP threshold against conventional clinical measures as predictors of exacerbations. RESULTS: A total of 67 individuals with asthma (27 males and 40 females, 28 with mild-to-moderate asthma and 39 with severe asthma) had a median VDP of 3.75% (1.2% [first quartile]-7.9% [third quartile]). An optimal VDP threshold of 4.28% was selected on the basis of the maximum likelihood estimation of the regression tree model. Subjects with a VDP greater than 4.28% (n = 32) had a median of 1.5 exacerbations versus 0.0 for subjects with a VDP less than 4.28% (n = 35). In a stepwise multivariate regression model, a VDP greater than 4.28% was associated with an exacerbation incidence rate ratio of 2.5 (95% CI = 1.3-4.7) versus a VDP less than or equal to 4.28%. However, once individual medical history was included in the model, VDP was no longer significant. Nonetheless, VDP may provide an objective and complementary quantitative marker of individual exacerbation risk that is useful for monitoring individual change in disease status, selecting patients for therapy, and assessing treatment response. CONCLUSION: VDP measured with magnetic resonance imaging shows promise as a biomarker of prospective asthma exacerbations.
BACKGROUND: There is an unmet need for an objective biomarker to predict asthma exacerbations. OBJECTIVE: Our aim was to assess the ventilation defect percent (VDP) on hyperpolarized helium-3 magnetic resonance imaging as a predictor of exacerbation frequency following imaging. METHODS: Subjects underwent hyperpolarized helium-3 and conventional clinical measurements, including pulmonary function tests, during a period of disease stability, and exacerbations were recorded prospectively over the following 2 years. We used a Poisson regression tree model to estimate an optimal VDP threshold for classifying subjects into high- versus low-exacerbation groups and then used statistical regression to compare this VDP threshold against conventional clinical measures as predictors of exacerbations. RESULTS: A total of 67 individuals with asthma (27 males and 40 females, 28 with mild-to-moderate asthma and 39 with severe asthma) had a median VDP of 3.75% (1.2% [first quartile]-7.9% [third quartile]). An optimal VDP threshold of 4.28% was selected on the basis of the maximum likelihood estimation of the regression tree model. Subjects with a VDP greater than 4.28% (n = 32) had a median of 1.5 exacerbations versus 0.0 for subjects with a VDP less than 4.28% (n = 35). In a stepwise multivariate regression model, a VDP greater than 4.28% was associated with an exacerbation incidence rate ratio of 2.5 (95% CI = 1.3-4.7) versus a VDP less than or equal to 4.28%. However, once individual medical history was included in the model, VDP was no longer significant. Nonetheless, VDP may provide an objective and complementary quantitative marker of individual exacerbation risk that is useful for monitoring individual change in disease status, selecting patients for therapy, and assessing treatment response. CONCLUSION:VDP measured with magnetic resonance imaging shows promise as a biomarker of prospective asthma exacerbations.
Authors: Eli O Meltzer; William W Busse; Sally E Wenzel; Vasily Belozeroff; Haoling H Weng; JingYuan Feng; Yun Chon; Chiun-Fang Chiou; Denise Globe; Shao-Lee Lin Journal: J Allergy Clin Immunol Date: 2010-11-18 Impact factor: 10.793
Authors: Sarah Svenningsen; Rachel L Eddy; Hui Fang Lim; P Gerard Cox; Parameswaran Nair; Grace Parraga Journal: Am J Respir Crit Care Med Date: 2018-04-01 Impact factor: 21.405
Authors: Wendy C Moore; Eugene R Bleecker; Douglas Curran-Everett; Serpil C Erzurum; Bill T Ameredes; Leonard Bacharier; William J Calhoun; Mario Castro; Kian Fan Chung; Melissa P Clark; Raed A Dweik; Anne M Fitzpatrick; Benjamin Gaston; Mark Hew; Iftikhar Hussain; Nizar N Jarjour; Elliot Israel; Bruce D Levy; James R Murphy; Stephen P Peters; W Gerald Teague; Deborah A Meyers; William W Busse; Sally E Wenzel Journal: J Allergy Clin Immunol Date: 2007-02 Impact factor: 10.793
Authors: Miranda Kirby; Damien Pike; Don D Sin; Harvey O Coxson; David G McCormack; Grace Parraga Journal: Radiology Date: 2015-07-07 Impact factor: 11.105
Authors: Nizar N Jarjour; Serpil C Erzurum; Eugene R Bleecker; William J Calhoun; Mario Castro; Suzy A A Comhair; Kian Fan Chung; Douglas Curran-Everett; Raed A Dweik; Sean B Fain; Anne M Fitzpatrick; Benjamin M Gaston; Elliot Israel; Annette Hastie; Eric A Hoffman; Fernando Holguin; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Stephen P Peters; Ronald L Sorkness; W Gerald Teague; Sally E Wenzel; William W Busse Journal: Am J Respir Crit Care Med Date: 2011-11-17 Impact factor: 21.405
Authors: Wendy C Moore; Deborah A Meyers; Sally E Wenzel; W Gerald Teague; Huashi Li; Xingnan Li; Ralph D'Agostino; Mario Castro; Douglas Curran-Everett; Anne M Fitzpatrick; Benjamin Gaston; Nizar N Jarjour; Ronald Sorkness; William J Calhoun; Kian Fan Chung; Suzy A A Comhair; Raed A Dweik; Elliot Israel; Stephen P Peters; William W Busse; Serpil C Erzurum; Eugene R Bleecker Journal: Am J Respir Crit Care Med Date: 2009-11-05 Impact factor: 21.405
Authors: Sean B Fain; Guillermo Gonzalez-Fernandez; Eric T Peterson; Michael D Evans; Ronald L Sorkness; Nizar N Jarjour; William W Busse; Janet E Kuhlman Journal: Acad Radiol Date: 2008-06 Impact factor: 3.173
Authors: Wei Zha; Stanley J Kruger; Robert V Cadman; David G Mummy; Michael D Evans; Scott K Nagle; Loren C Denlinger; Nizar N Jarjour; Ronald L Sorkness; Sean B Fain Journal: Acad Radiol Date: 2017-11-23 Impact factor: 3.173
Authors: David G Mummy; Eleanor M Dunican; Katherine J Carey; Michael D Evans; Brett M Elicker; John D Newell; David S Gierada; Scott K Nagle; Mark L Schiebler; Ronald L Sorkness; Nizar N Jarjour; Loren C Denlinger; John V Fahy; Sean B Fain Journal: Radiology Date: 2021-12-21 Impact factor: 29.146
Authors: Marcello Cottini; Carlo Lombardi; Giovanni Passalacqua; Diego Bagnasco; Alvise Berti; Pasquale Comberiati; Gianluca Imeri; Massimo Landi; Enrico Heffler Journal: Front Med (Lausanne) Date: 2022-05-23
Authors: Grace T Mussell; Helen Marshall; Laurie J Smith; Alberto M Biancardi; Paul J C Hughes; David J Capener; Jody Bray; Andrew J Swift; Smitha Rajaram; Alison M Condliffe; Guilhem J Collier; Chris S Johns; Nick D Weatherley; Jim M Wild; Ian Sabroe Journal: ERJ Open Res Date: 2021-09-27
Authors: Neil J Stewart; Laurie J Smith; Ho-Fung Chan; James A Eaden; Smitha Rajaram; Andrew J Swift; Nicholas D Weatherley; Alberto Biancardi; Guilhem J Collier; David Hughes; Gill Klafkowski; Christopher S Johns; Noreen West; Kelechi Ugonna; Stephen M Bianchi; Rod Lawson; Ian Sabroe; Helen Marshall; Jim M Wild Journal: Br J Radiol Date: 2021-06-09 Impact factor: 3.629